Clinical Trial: Mucinex® for Treatment of Filamentary Keratitis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Mucinex® for Treatment of Filamentary Keratitis

Brief Summary: It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Detailed Summary: The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.
Sponsor: Massachusetts Eye and Ear Infirmary

Current Primary Outcome: Mucinex® for the treatment of filamentary keratitis [ Time Frame: 1 month ]

Reduction of symptoms according to the ocular surface disease index score after treatment with oral Mucinex® twice a day for 4 weeks


Original Primary Outcome: Same as current

Current Secondary Outcome: Mucinex® for the treatment of filamentary keratitis [ Time Frame: 1 month ]

Reduction in the number of corneal filaments after treatment with oral Mucinex® twice a day for 4 weeks.


Original Secondary Outcome: Same as current

Information By: Massachusetts Eye and Ear Infirmary

Dates:
Date Received: August 4, 2016
Date Started: September 2016
Date Completion: July 2017
Last Updated: March 24, 2017
Last Verified: March 2017